Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 17/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | HRH1 | P35367 | 8/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077011 | 0.85 | DRD3 (0.44) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL11249229 | 0.77 | ALDH1A1 (0.55) | — | |
| SCHEMBL19612435 | 0.74 | HSD11B1 (0.38) | DRD3KCNH2DRD2 | |
| SCHEMBL12377972 | 0.74 | HSD11B1 (0.35) | — | |
| SCHEMBL378206 | 0.73 | KCNH2 (0.61) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL1883008 | 0.72 | DRD3 (0.41) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL2307186 | 0.72 | KCNH2 (0.60) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL378177 | 0.71 | KDM4E (0.66) | — | |
| SCHEMBL7483228 | 0.71 | CYP1A2 (0.50) | — | |
| SCHEMBL4877877 | 0.69 | CYP1A2 (0.46) | DRD3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| EP-1737851-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005087764-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | DRD3, HTR3C, GRIN3A | DRD3 1/4885KCNH2 162/4885DRD2 8/4885 |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | DRD3 1/4885KCNH2 399/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.